TARS
TARS
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
37
$25.89M
Total Volume
$25.89M
37 transactions
Net Activity
$25.89M
Net selling
Sentiment Rating
Heavy DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Azamian Bobak R.
Pres, CEO, Board Chair
$7.28M total
Link William J Phd
Dir
$6.03M total
Whitfield Dianne C.
CHRO
$3.01M total
Neervannan Seshadri
COO
$2.36M total
Mottiwala Aziz
Chief Commercial Officer
$2.16M total
Quick Actions
TARS has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at TARS (TARS) engaged in a total of 37 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 37 were sales. The total volume of insider trading reached $25.89M.
The net insider activity for TARS shows a net selling bias of $25.89M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Azamian Bobak R. (Pres, CEO, Board Chair), who traded 34.6K shares valued at $2.36M on Mar 17, 2026.
Tarsus Pharmaceuticals (TARS) Stock Looks Cheap On Its 342% Run
6 Green Days In A Row: Tarsus Pharmaceuticals Stock Is Up 19%
Tarsus plans two investor talks, in November and December
Tarsus Pharmaceuticals (TARS) Stock May Trade At A Discount On Strong Sales Growth
Tarsus: Not Cheap, But Xdemvy Makes The Valuation Work
TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme
FAQs About TARS Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for TARS.